1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) October 20, 1995
------------------------
SUMMIT TECHNOLOGY, INC.
-------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
MASSACHUSETTS 0-16937 04-2897945
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
21 HICKORY DRIVE
WALTHAM, MASSACHUSETTS 02154
---------------------------------------------------
(Address of Principal Executive Offices)
Registrant's telephone number, including area code (617) 890-1234
--------------
2
ITEM 5. OTHER EVENTS.
On October 20, 1995, the Company received Food and Drug Administration
("FDA") approval to commercially market and sell the Company's excimer laser
for Photorefractive Keratectomy ("PRK") for laser correction of
nearsightedness. The approval covers the use of the Company's excimer laser to
perform PRK for laser correction of nearsightedness from -1.5 to -7 diopters
using a six millimeter ablation zone. The Company is the first and only
company in the ophthalmic excimer laser field to receive FDA approval to
commercially market and sell excimer laser systems in the U.S. for treating
nearsightedness.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SUMMIT TECHNOLOGY, INC.
BY:/s/ David F. Muller
------------------------------------
David F. Muller, President
DATE: October 23, 1995